Esophagus Cancer Clinical Trial
Official title:
Qizhu Yuling Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Esophagus Cancer:A Randomized, Double-blind, Controlled and Multi-center Clinical Study
The purpose of this study is to evaluate the efficacy and safety of Qizhu Yuling prescription for postoperative esophagus cancer.
This study include a multi-center, randomized, double-blind, placebo, parallel controlled clinical trial.The randomized clinical trial will enroll approximately 310 patients. Participants will be randomly divided into experimental (n=155) and placebo groups (n=155).Patients in the experimental group was treated with Qizhu Yuling prescription within 6 months after esophagus cancer R0. Patients in the control group will receive the placebo.The primary endpoint is 1-year DFS (Disease-free survival) rate after surgery, that refers to the proportion of patients who do not have recurrence, metastasis or death (from any cause) within 1 years after surgery. The research protocol was approved by the relevant ethics committees, and the study was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. Patients gave written informed consent to participate in the trial. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Completed |
NCT00201747 -
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
|
Phase 2 | |
Recruiting |
NCT06036563 -
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
|
||
Not yet recruiting |
NCT05023928 -
Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer
|
Phase 1 | |
Recruiting |
NCT03941626 -
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Recruiting |
NCT02988921 -
MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy
|
N/A | |
Terminated |
NCT02797405 -
Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay
|
N/A | |
Completed |
NCT02979691 -
Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01
|
Phase 2/Phase 3 | |
Recruiting |
NCT03347630 -
Pre-operative MRI of Esophagus Cancer
|
N/A | |
Completed |
NCT00193141 -
Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer
|
Phase 2 | |
Completed |
NCT05615129 -
Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
|
||
Recruiting |
NCT04821765 -
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
|
Phase 2 | |
Terminated |
NCT03108885 -
Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
|
||
Recruiting |
NCT04046575 -
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
|
Phase 1 | |
Recruiting |
NCT06126406 -
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
|
Phase 1 | |
Completed |
NCT03467529 -
Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study
|
||
Completed |
NCT02552121 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02001623 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT06160557 -
A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma
|